North America accounts for a significant share of the Antineoplastic Interferon Drug Market, supported by its advanced oncology care infrastructure, strong biotechnology ecosystem, and substantial investments in cancer research. The United States and Canada continue to lead the region with extensive clinical trial activity, well-established pharmaceutical manufacturing capabilities, and...